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esponsibility of InstAbstract Histone acetylation is a critical process in the regulation of chromatin structure and gene expression.
Histone deacetylases (HDACs) remove the acetyl group, leading to chromatin condensation and transcriptional
repression. HDAC inhibitors are considered a new class of anticancer agents and have been shown to alter gene
transcription and exert antitumor effects. This paper describes our work on the structural determination and
structure-activity relationship (SAR) optimization of tetrahydroisoquinoline compounds as HDAC inhibitors.
These compounds were tested for their ability to inhibit HDAC 1, 3, 6 and for their ability to inhibit the
proliferation of a panel of cancer cell lines. Among these, compound 82 showed the greatest inhibitory activity
toward HDAC 1, 3, 6 and strongly inhibited growth of the cancer cell lines, with results clearly superior to those
of the reference compound, vorinostat (SAHA). Compound 82 increased the acetylation of histones H3, H4 and
tubulin in a concentration-dependent manner, suggesting that it is a broad inhibitor of HDACs.
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Danqi Chen et al.94Histone acetylation is a critical process in the regulation of
chromatin structure and gene expression. In general, histone
acetyltransferases (HATs) transfer acetyl groups to amino-
terminal lysines in histones, which results in local expansion
of chromatin and increases the accessibility of regulatory
proteins to DNA, whereas histone deacetylases (HDACs)
remove the acetyl groups, leading to chromatin condensation
and transcriptional repression1,2. HDAC inhibitors are con-
sidered as a new class of anticancer agents and have been
shown to alter gene transcription and exert antitumor effects,
such as growth arrest, differentiation, apoptosis and inhibition
of tumor angiogenesis. The reported HDAC inhibitors include
hydroxamates, benzamides, cyclic peptides, thiols and sulpha-
mides, some of which have been approved for use, such as
Vorinostat (SAHA)3, Belinostat4, Panobinostat5, Romidepsin6
and Chidamide (Fig. 1). Among these drugs Vorinostat,
Belinostat and Panobinostat are hydroxamates, indicating thatFigure 1 Launched drugs targeting HDAC a
Scheme 1 Synthetic routes of HDAC inhibitors 58–83. Reagen
(ii) polyphosphoric acid, 120 1C; (b) fuming HNO3, conc. H2SO4, 0 1C
dimethylformamide, 80 1C; (f) methyl acrylate, Pd2(dba)3, tris(o-toIyl)ph
KOH, MeOH.this chemical group is an effective pharmacophore for HDAC
inhibitors. These inhibitors generally have three characte-
ristic structural features: a critical zinc-binding region, a
hydrophobic region referred as CAP, and a linker between
these two regions7.
In our previous work we designed a software called CCLab
(Combinatorial Chemistry Laboratory) and applied it for the
identiﬁcation of new chemical scaffolds of HDAC inhibitors8.
Based on the screening results, the scaffold of tetrahydroisoquino-
line (Fig. 1) was selected for further optimization.
The synthesis route is outlined in Scheme 1. The starting
material phenethylamine was treated with methyl chloroformate
and the intermediate product underwent cyclization to give 2.
Compound 2 was nitrated by a mixture of fuming nitric acid and
concentrated sulfuric acid to yield 3. Compound 4 was the
reductive product of 3. Compound 4 was treated with tert-butyl
nitrite and cupric bromide to give 5. Compound 5 coupled withnd the scaffold of tetrahydroisoquinoline.
ts and conditions: (a) (i) ClCOOMe, Et3N, dichloromethane;
; (c) H2, Pd/C; (d) t-BuONO, CH3CN, 80 1C; (e) RBr, NaH, N,N-
osphine, Et3N, N,N-dimethylformamide, 120 1C; (g) NH2OH HCl,
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Scheme 2 Synthetic procedure of compound 88. Reagents and conditions: (a) NaH, benzyl bromide, N,N-dimethylformamide, 100 1C; (b) BBr3,
dichloromethane, r.t.; (c) (i) triﬂuoromethanesulfonic anhydride, dichloromethane, 0 1C to r.t.; (ii) methyl acrylate, Pd2(dba)3, tris(o-toIyl)-
phosphine, Et3N, N,N-dimethylformamide, 120 1C; (d) NH2OH HCl, KOH, MeOH.
Table 1 Inhibition on HDAC1, 3 and 6 of compound 58 and 88.
Compd. Structure IC50 (mmol/L)
HDAC1 HDAC3 HDAC6
SAHA 0.06±0.02 0.09±0.02 0.16±0.02
58 0.22±0.05 0.20 0.18±0.03
88 0.47±0.05 0.37±0.04 2.14±0.17
All assay data are reported as the average of at least two measurements.
Tetrahydroisoquinolines as novel HDAC inhibitors 95different bromides to obtain 6–31, which were further modiﬁed
through the Heck reaction with methyl acrylate to yield
compounds 32–57. These compounds reacted with hydroxyla-
mine in methanolic solution to afford the desired compounds
58–839.
Compound 88 was prepared following the steps in
Scheme 2. 6-Methoxy-3,4-dihydroisoquinolin-1(2H)-one and
benzyl bromide were treated with NaH to give compound 85,
which was demethylated in the presence of BBr3 to yield
compound 86. Compound 86 was treated with triﬂuorometha-
nesulfonic anhydride to give the corresponding ester which
was further modiﬁed in the Heck reaction with methyl acrylate
to yield compound 87. Compound 87 reacted with hydroxy-
lamine in methanolic solution to afford the desired compound
88.
The N-hydroxyacrylamide moiety can link to the tetrahydroi-
soquinoline ring at different positions. At the beginning we
intended to investigate the impact of different positions of
modiﬁcation on activities (Table 1). When substituted at the
7-position, the compound (58) yielded slightly better results than
the corresponding modiﬁcation at the 6-position on the three tested
members of HDACs (HDAC 1, 3 and 6). Thus we chose
7-position for further derivatives.
The benzyl group of 58 is hypothesized to be the CAP region.
As the known HDAC inhibitors differ greatly in this moiety, weintroduced different kinds of fragments to this region including
substituted benzyl groups, alkyl groups and cycloalkyl groups
for preliminary structure-activity relationship (SAR) information
(Table 2).
All the compounds with different kinds of R groups
exhibited inhibitory activity with HDAC1, 3, and 6. Longer
linear alkyl groups showed a small decrease in activity (62).
Cycloalkyl groups (63, 64) showed activity equivalent to that
of the benzyl groups. Compounds with electron-withdrawing
or electron-donating substitutions on the benzyl groups
demonstrated similar activities on HDAC1, 3, and 6. However,
when two methyl groups were introduced (71) the IC50 of
HDAC1 was increased up to 80 nmol/L while IC50 of HDAC6
decreased to the mmol/L level. As reported, there are residues
that may produce π-π stacking interactions with the CAP
region10–12. Thus we chose 58 as the hit compound to
elaborate the impact of subtle modiﬁcations to the phenyl ring
(Table 3).
When the phenyl ring was substituted by a pyridyl group (72),
the inhibition of HDAC1 decreased markedly. When another
phenyl ring or pyridyl ring was introduced to the 4-position of
the benzyl group (74–76), the compounds maintained inhibitory
activity, superior to that obtained with the substitution in the 2-
position (77). When two more carbon atoms were introduced
between the benzyl group and the tetrahydroisoquinoline ring (79)
Table 2 Inhibition on HDAC1, 3 and 6 of compound 57–371.
R
N N
O O
OH
H
All assay data are reported as the average of at least two measurements.
Danqi Chen et al.96the inhibition on HDAC1, 3 and 6 increased and became
equivalent to marketed drug SAHA.
As compound 79 showed activity comparable to SAHA, it
was evaluated for its effect on cancer cell proliferation.
Seventeen cell lines were tested. Most of the IC50 values were
less than 5 mmol/L and some of them were less than 1 mmol/L.
Compound 79 showed inhibition equivalent to that of SAHA
(Table 4)13.
The introduction of the phenylpropyl group enhanced the
activity and showed stronger inhibition than that of SAHA,
which made compound 79 a promising compound for further
investigation. Several substitutions were introduced in the
phenyl ring (Table 5). Substitutions in the 4-position made an
obvious improvement in the inhibition of HDAC1 and 3, and
the IC50 of 81 and 82 was less than 100 nmol/L. Compound 82,
together with 79 and SAHA were submitted to testing on apanel of cancer cell lines for comparison (Fig. 2).
As illustrated in Fig. 2, Compound 82 strongly inhibited
the proliferation of all 8 cell lines, which was clearly
superior to SAHA. The introduction of a methoxy group in
the phenyl ring also enhanced the activity as compared to
compound 79.
One of the important functions of HDACs is to deacylate
histones and thereby suppress gene expression. As reported,
SAHA increased the acetylation of histone H3, H4 and tubulin
after 24 h treatment in HCT-116 colorectal cancer cells. Com-
pound 82 also increased the acetylation of histones H3, H4 and
tubulin in a concentration-dependent manner (Fig. 3), conﬁrming
that it is a pan-inhibitor of HDAC.
In summary, the scaffold of tetrahydroisoquinoline was selected
from our previous work and submitted for SAR investigation. The
linkage between N-hydroxyacrylamide and the tetrahydroisoquino
Table 4 IC50 values of compound 79 and SAHA in cancer cell lines (mmol/L).
Cell lines SAHA 79
HeLa 3.6270.27 2.5370.75
BEL-7402 3.0170.53 1.5070.09
SMMC-7721 2.6871.03 2.7671.32
SGC-7901 2.8471.67 2.3870.61
MKN28 2.2170.84 1.4070.55
A549 3.7971.98 2.2871.00
MCF-7 2.0871.19 0.9370.317
MDA-MB-468 2.9871.25 1.5770.96
PC3 5.4371.78 1.9470.24
U251 10.0871.45 7.6872.31
A431 2.0770.13 2.3170.41
A375 1.8670.42 2.0971.20
T24 2.1871.09 4.0170.90
SK-OV-3 3.5770.74 1.0470.38
BxPC3 2.2470.61 1.0470.38
786-O 4.0171.30 3.8372.18
GES-1 1.1270.11 0.5770.23
Table 3 Inhibition on HDAC1, 3 and 6 of compound 72–79.
R
N N
H
OH
O O
All assay data are reported as the average of at least two measurements.
Tetrahydroisoquinolines as novel HDAC inhibitors 97line ring was better at the 7-position than the 6-position.
Compounds with a phenylpropyl group in the CAP region
exhibited good activities on HDAC1, 3 and 6, and furthermodiﬁcation of the phenyl group gave compound 82, which
showed excellent HDAC inhibition and strong inhibition of
proliferation of several cancer cell lines.
Figure 2 IC50 values of compound 79, 82 and SAHA on cancer cell
lines (mmol/L).
Figure 3 Increased acetylated histones and tubulin levels in com-
pound 82 and SAHA treated HCT-116 colorectal cancer cells. HCT-
116 cells were treated with various concentrations of compound 82
and SAHA for 24 h, proteins extracted, and analyzed for Ac-H3, Ac-
H4 and Ac- tubulin by Western Blot14.
Table 5 Inhibition on HDAC1, 3 and 6 of compound 80–83.
R
N N
H
OH
OO
All assay data are reported as the average of at least two measurements.
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